27 results about "Aescin" patented technology

This invention discloses a acne-repairing and repairing composition specifically developed for adolescents and its application, relating to the field of cosmetic technology. The invention provides an acne-repairing and repairing composition comprising 5-12 parts of guaiac extract, 1-6 parts of eggplant extract, 0.001-0.01 parts of aescin, 0.01-0.1 parts of diosgenin, and 0.01-0.1 parts of asiaticoside. This invention achieves a three-dimensional synergistic effect of "anti-inflammatory, repair, and metabolic regulation" through the synergistic interaction of five components: guaiac extract, eggplant extract, aescin, diosgenin, and asiaticoside, forming a comprehensive management system for acne and post-acne repair in adolescents.

The invention relates to the technical field of eutectic crystals, in particular to an aesculin and mannitol eutectic crystal and a preparation method and application thereof.The XRD spectrum of the eutectic crystal at least has characteristic diffraction peaks at the positions where the angle 2 theta is 13.80 degrees, 17.41 degrees, 18.87 degrees, 19.99 degrees, 20.55 degrees, 21.46 degrees, 25.29 degrees, 27.15 degrees, 27.66 degrees, 28.30 degrees, 33.32 degrees, 34.13 degrees, 35.67 degrees, 36.33 degrees, 36.80 degrees and 44.06 degrees, and error tolerance of + / -0.2 degrees exists; characteristic endothermic peaks exist at 167.5 DEG C and 327 DEG C in a DSC spectrum, and error tolerance of + / -0.2 DEG C exists. The preparation method comprises the following steps: dissolving mannitol and escin in deionized water, heating and stirring, and carrying out high-temperature and high-pressure reaction, standing, crystallizing, filtering and drying to obtain the eutectic crystal which can be applied to cosmetics, health-care products, foods and medicines. The eutectic crystal provided by the invention has the advantages of no irritation, high safety, easy absorption and good stability.

The invention discloses a joint health-care tablet based on glucosamine hydrochloride and sodium chondroitin sulfate and a preparation method, and relates to the technical field of medical health care. The joint health-care tablet comprises the following components: glucosamine hydrochloride, sodium chondroitin sulfate, a frankincense extract, an aesculus chinensis extract, microcrystalline cellulose, povidone, croscarmellose sodium and silicon dioxide. Through scientific proportioning of various active components such as the glucosamine hydrochloride, the chondroitin sulfate sodium, the frankincense extract and the aesculus chinensis extract, comprehensive protection of joint health is realized, the glucosamine hydrochloride and the chondroitin sulfate sodium are used as basic components, repair and regeneration of articular cartilage are promoted, and the joint health is improved. Boswellic acid compounds in the frankincense extract and aescin in the aesculus chinensis extract have anti-inflammatory and analgesic effects and can effectively relieve arthralgia and inflammation, multiple effects are synergistic, and the joint health care effect is improved.

This invention discloses a composition for relieving allergies, itching, and improving rough skin, its preparation method, and its application. The composition comprises the following active ingredients: asiaticoside, centella asiatica extract, kava extract, aescin, allantoin, and sodium hyaluronate. This invention prepares the composition using raw materials and proportions containing asiaticoside, centella asiatica extract, kava extract, aescin, allantoin, and sodium hyaluronate. The synergistic effect between these components results in excellent anti-allergic, anti-itch, and skin-roughening effects. After preparing the composition into a soothing and anti-itch cream, tests showed that it significantly reduced the a* value and lactic acid stinging score of sensitive skin. Doctor evaluation methods further confirmed its significant improvement effects on burning, erythema, swelling, peeling, stinging, and itching of sensitive skin, while also showing a significant effect on improving rough skin.

The present application relates to the technical field of biological medicine, and more particularly to the application of isodon japonicus in the preparation of a drug for preventing and treating spontaneous abortion. The present application analyzes the in-vivo migration components of Jianwei Shoutai Pills, excavates the pharmacodynamic material basis for preventing and treating spontaneous abortion, and uses a CBA / J x DBA / 2 peri-implantation period abortion mouse model to conduct pharmacodynamic experiments. The results show that isodon japonicus can significantly reduce the abortion rate of the CBA / J x DBA / 2 peri-implantation period abortion model mice, and can effectively increase the embryo and placenta wet weight of the CBA / J x DBA / 2 peri-implantation period abortion model mice. That is, isodon japonicus can effectively inhibit spontaneous abortion, has a significant curative effect, has considerable treatment potential, provides a potential new drug selection for clinical drugs for preventing and treating spontaneous abortion, and has a broad application prospect.

The invention belongs to the technical field of medical care, and relates to a composition for dispelling effects of alcohol and protecting liver, application of the composition, a microneedle composition and a preparation method. The alcohol effect dispelling and liver protecting composition is prepared from the following components in parts by weight: 10 to 30 parts of glutathione, 3 to 12 parts of vitamin B, 10 to 30 parts of vitamin C derivative, 5 to 15 parts of taurine, 0.5 to 1.5 parts of aescin and 3 to 7.5 parts of red ginseng extract. The application refers to the application of the alcohol effect dispelling and liver protecting composition in preparation of an external product for dispelling the alcohol effect and protecting the liver. The microneedle composition takes the alcohol effect dispelling and liver protecting composition as an active ingredient. According to the invention, glutathione, B vitamins, vitamin C derivatives, taurine, aescin and red ginseng extract are taken as main components, so that the anti-alcoholism liver-protecting composition has good anti-alcoholism and liver-protecting effects, and also can promote detoxification and detoxification functions of the liver. Meanwhile, the composition for dispelling the effects of alcohol and protecting the liver is combined with the soluble microneedle, and through painless transdermal administration, the dosage is smaller, and the composition has better patient compliance.

The invention relates to the technical field of biological materials, in particular to lipid nanoparticles based on modified natural saponin, a preparation method and application of the lipid nanoparticles, and the modified natural saponin comprises natural saponin modified by metal complexes and / or natural saponin modified by targeting molecules. The natural saponin is selected from at least one of glycyrrhizic acid, aescin, soyasaponin, ginsenoside, ursolic acid and oleanolic acid. The modified natural saponin can effectively simulate the structural function of cholesterol compounds in lipid nanoparticles, can overcome the problems of unstable physicochemical properties of cholesterol, potential safety hazards of sources and the like, and can significantly improve the gene transfection and silencing efficiency of nucleic acid drugs as a drug carrier. And a new solution is provided for gene therapy and vaccine development. The preparation method of the lipid nanoparticles based on the modified natural saponin is mild in reaction condition, simple and convenient to operate, easy to control and beneficial to industrial production.

The invention relates to the technical field of supramolecules, in particular to a ginsenoside CK-aescin supramolecule, in the supramolecule, ginsenoside CK and aescin are formed through a non-covalent bond, the mass ratio of ginsenoside CK to aescin is 1: (1-25), and a preparation method comprises the following steps: dispersing aescin in an organic solvent aqueous solution to prepare a suspension A, dissolving ginsenoside CK in ethanol to prepare a solution D for later use; stirring the suspension A to obtain a suspension B; performing ultrasonic treatment on the suspension B to obtain emulsion C; slowly adding the emulsion C into the solution D while stirring, stirring to obtain a ginsenoside CK-aescin supramolecular solution crude product, and dialyzing. According to the ginsenoside CK-aescin supramolecule prepared by the invention, an IVPT test shows that the transdermal absorption capacity of the ginsenoside CK-aescin supramolecule is remarkably improved, so that the ginsenoside CK-aescin supramolecule can be better absorbed by human skin, and the efficacy of the ginsenoside CK-aescin supramolecule is favorably exerted.

The invention belongs to the technical field of medicines, and finds an application of a compound esculetin as shown in a formula I and a precursor thereof in preparation of a medicine for promoting repair of dyskinesia and neurological impairment in a subacute stage-recovery stage after cerebral arterial thrombosis. It is found that the compound esculetin can significantly reduce the area and volume of infarction after cerebral arterial thrombosis and promote repair of dyskinesia and neurological impairment after cerebral arterial thrombosis, which is shown in improvement of sensory movement and posture asymmetry after cerebral arterial thrombosis and enhancement of forelimb movement function and limb coordination. The esculetin can be used for remarkably reducing neuron injury caused by cerebral ischemia. The compound can be used for preparing medicines for promoting the repair of dyskinesia and neurological function damage in the subacute stage-recovery stage after cerebral apoplexy.

This invention discloses a method for preparing and applying aescin in cosmetics, belonging to the field of plant active ingredient extraction technology. The method for preparing aescin includes the following steps: adding horse chestnut seeds to an organic solvent, then adding an alkaloid, heating and refluxing to extract, and then removing the organic solvent to obtain a crude extract; dissolving the crude extract in water, adding a cyclic oligosaccharide, stirring and reacting, then adding an organic acid, heating and reacting, and finally purifying to obtain aescin. The preparation method of this invention can improve both the extraction rate and retention rate of aescin.

The invention belongs to the technical field of biological medicines, and particularly relates to application of aescin in preparation of a product for inducing autophagy of skin cells. According to the application disclosed by the invention, research finds that aescin can induce autophagy of skin keratinocytes for the first time, and the expression level of autophagy-related proteins LC3-I and LC3-II in the skin keratinocytes can be remarkably improved; in addition, aescin and ursolic acid have a synergistic effect in the aspect of inducing skin keratinocyte autophagy, and are safe and non-irritant to skin. Therefore, the aescin and the composition of the aescin and the ursolic acid can be used for preparing products for inducing autophagy of skin cells so as to resist aging, remove freckles, whiten skin, control oil and strengthen a skin cuticle barrier, and products for slowing down a scleroderma process / relieving a scleroderma symptom, slowing down an atopic dermatitis process / relieving an atopic dermatitis symptom and relieving acne. The traditional Chinese medicine composition has the advantages of remarkable curative effect and high safety.

The invention provides UDP-glucose transferase for catalyzing glycosylation at C2'site of aescin, a gene, a primer group and application, and belongs to the technical field of aescin. The method is based on aesculus chinensis genome and transcriptome data analysis; according to the present invention, the UGT gene for catalyzing the C2'site of the protoaescinogenin-3-O-beta-D-glucopyranuronide is excavated, and the tobacco transient expression system is utilized to verify that the AcUGT94AK1, the AcUGT94AK3 and the AcUGT94AK6 can catalyze the protoaescinogenin-3-O-beta-D-glucopyranuronide to form the protoaescinogenin-3-O-beta-D-glucopyranuronide-(1-> 2)-beta-D-glucoside, such that the UGT gene can be used for catalyzing the C2 'site of the protoaescinogenin-3-O-beta-D-glucopyranuronide; the invention not only provides an important gene element for biosynthesis of aescin compounds, but also provides a key gene locus for molecular breeding of aesculus chinensis, and provides a theoretical basis for glycosylation modification of other triterpenoid saponins.

The invention relates to an application of an NKT-like cell in the onset of primary sicca syndrome. The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating primary sicca syndrome. The invention relates to a pharmaceutical composition for treating primary sicca syndrome. The pharmaceutical composition is prepared from artemisia vulgaris and a total glucosides capsule of radix paeoniae alba. The total glucosides of paeony capsule is combined with iguratimod to treat the primary sicca syndrome, so that the saliva flow rate and tear flow rate of a patient can be effectively improved, the NKT-like cell content is increased, the body immune function is enhanced, the improvement of clinical symptoms is promoted, the clinical treatment effect is remarkably improved, and the total glucosides of paeony capsule is worthy of clinical popularization.

The invention discloses acyltransferase AcBAHD13 participating in synthesis of aescin A as well as a coding gene and application of the acyltransferase AcBAHD13. The amino acid sequence of acyltransferase protein is shown as SEQ ID NO: 2. The nucleotide sequence of the coding gene of the acyltransferase protein is shown as SEQ ID NO: 1. The invention relates to the technical field of biotechnology. According to the acyltransferase AcBAHD13 participating in synthesis of aescin A as well as the coding gene and the application of the acyltransferase AcBAHD13, an AcBAHD13 gene is obtained based on aescin genome and transcriptome data screening, a pET28a-AcBAHD13 prokaryotic expression vector is constructed and is subjected to induced expression, and the acylation function of the AcBAHD13 is verified in vitro by taking proaescin as a substrate. The result proves that the AcBAHD13 can be used for catalyzing the proaescin to generate the 21-O-angeloyl proaescin by utilizing an exogenous angeloyl donor, and a foundation is laid for the biological research on synthesis of aescin components with important medicinal values.

The invention discloses an application of beta-aescin in prevention of heart injury caused by long-term diving. A medicine for preventing heart injury caused by long-term diving is a medicine composition which takes beta-aescin as a unique active ingredient or contains beta-aescin. According to the application of the beta-aescin to prevention of heart injury caused by long-term phreatic water, animal in-vivo experiment results show that the myocardial infarction area of a long-term simulated phreatic water rat model is remarkably reduced by 14.9 + / -7.7% to 6.5 + / -3.4% through administration of the beta-aescin, and although no statistical difference exists, the morbidity is reduced from 44.8% to 28.0%, so that the myocardial infarction area of the long-term simulated phreatic water rat model is obviously reduced by 14.9 + / -7.7% to 6.5 + / -3.4%. The right ventricular hypertrophy index is reduced from 34.5 + / -12.2% to 22.6 + / -5.6%, which indicates that the beta-aescin can effectively prevent rat heart injury caused by long-term diving. Therefore, the beta-aescin has a good application prospect in prevention of heart injury caused by long-term diving.

The invention discloses application of ziyuglycoside II in preparation of a medicine for treating and relieving acute promyelocytic leukemia and / or ATRA-resistant acute promyelocytic leukemia and a medicine composition, and belongs to the technical field of medicine. Experiments prove that ziyuglycoside II can inhibit proliferation of acute promyelocytic leukemia cells (NB4) and transretinoic acid (ATRA) drug-resistant acute promyelocytic leukemia cells (NB4-R2), induce differentiation of the NB4 and the NB4-R2, promote apoptosis of the NB4-R2 cells and relieve disease development of ATRA drug-resistant cell xenotransplantation acute promyelocytic leukemia. The ziyuglycoside II is developed as a novel drug for resisting acute promyelocytic leukemia or an auxiliary component thereof, and the ziyuglycoside II has obvious effects of resisting acute promyelocytic leukemia and drug-resistant acute promyelocytic leukemia; the invention provides a new approach and means for treating acute promyelocytic leukemia and drug-resistant acute promyelocytic leukemia.

This invention provides a horse chestnut tiglyl-CoA ligase gene. AcCCL3 This invention relates to the AcCCL3 protein and its applications, belonging to the field of gene technology. For the first time, this invention has identified and verified the key enzyme gene responsible for the biosynthesis of tigrazol-CoA in horse chestnut. AcCCL3 This invention provides a complete analysis of its biosynthetic pathway, filling a knowledge gap in this field. It can be based on... AcCCL3 This gene, through synthetic biology strategies and an engineered system, has achieved the synthesis of tiglyl-CoA, completely eliminating reliance on traditional, complex, and demanding chemical synthesis routes. This significantly reduces production costs from the source, enabling large-scale production and successfully solving the core challenge of large-scale, stable preparation and supply of tiglyl-CoA. It also breaks through the key precursor constraints that have hindered the biosynthetic research, drug development, and industrial production of a series of high-value aescin compounds, represented by aescin A.

The invention belongs to the technical field of application of natural compounds, and particularly relates to novel application of aescin. Aescin is applied to preparation of the atherosclerosis medicine for cardiovascular diseases, reduction of AMPK phosphorylation induces increase of p-mTOR expression, reduction of autophagy causes accumulation of cholesterol in macrophage-derived foam cells, and finally occurrence and development of atherosclerosis are promoted. According to the application, AMPK is activated through aescin, mTOR phosphorylation is reduced to induce autophagy of the macrophage-derived foam cells, ABCA1 protein expression is up-regulated, cholesterol outflow of the macrophage-derived foam cells is promoted, and therefore atherosclerosis is improved.

This invention discloses the application of aescin in the preparation of a feed repellent for fruit flies. This invention is the first to propose that the natural plant medicine aescin can be used as an insect feed repellent. Verification has shown that it has a significant feeding repellent effect on both adult and larval fruit flies, making it suitable as a feed repellent for fruit fly pests. Further development into a natural drug for controlling fruit fly pests is possible. It is non-toxic and pollution-free to various crops, vegetables, fruits, and other economic crops, will not induce drug resistance, and will not pollute the environment or harm human health, demonstrating excellent application prospects.

The invention provides a 4 '-O-glucose glycosyl transferase AcUGT87AZ3 protein in an aesculus chinensis triterpene synthesis pathway, an AcUGT87AZ3 gene and application of the AcUGT87AZ3 protein and the AcUGT87AZ3 gene, and belongs to the technical field of biology. The method is combined with transcriptome data analysis; the UGT gene capable of catalyzing the 4 '-O-glucose glycosylation of 3 beta-O-{beta-D-glucopyranoglucuronic acid}-protoaescin, geligillaceae saponin IC or 21 beta-O-tigillaceae acyl-22 alpha-O-acetyl-geligillaceae saponin IC is obtained through screening, and the UGT gene can be used for catalyzing the 4'-O-glucose glycosylation of the geligillaceae saponin IC. An escherichia coli in-vitro enzyme activity experiment and a tobacco transient expression system verify that the AcUGT87AZ3 can catalyze the synthesis of 3 beta-O-{[beta-D-glucopyranose-(1-4)]-beta-D-glucopyranuronic acid}-proaescin, aescin B and aescin A. The AcUGT87AZ3 can catalyze the synthesis of 3 beta-O-{[beta-D-glucopyranose-(1-4)]-beta-D-glucopyranuronic acid}-proaescin.

The invention particularly discloses a composition and application thereof in preparation of a product with an effect of improving the activity of lymphatic endothelial cells. The composition is prepared from a schisandra chinensis fruit extract and aescin, the weight ratio of the schisandra chinensis fruit extract to the aescin is (1-3): (0.1-0.3). Furthermore, the composition also comprises a passion fruit extract. The weight ratio of the schisandra chinensis fruit extract to the passion fruit extract to the aescin is (1-3): (1-3): (0.1-0.3). Researches show that the composition can improve the activity of lymphatic endothelial cells by enhancing the mitochondrial function and promoting cell autophagy. The composition disclosed by the invention has the effect of improving the activity of lymphatic endothelial cells; therefore, the compound has important application value when being used as an active ingredient for preparing medicines or cosmetics with the effect of improving the activity of lymphatic endothelial cells.

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.

The present application relates to the field of medicine, and more particularly to the use of aesculin or verbascoside in the preparation of a medicament for treating and / or preventing IgAN. The present inventors have found that aesculin and / or verbascoside can significantly improve proteinuria caused by IgAN and reduce inflammatory reactions, thereby playing a role in protecting kidney function, and do not have the serious shortcomings of clinically commonly used drugs, indicating that aesculin and / or verbascoside have a strong and low-toxicity effect in treating IgAN. In addition, aesculin and / or verbascoside are a natural compound, low toxicity and easy to be accepted by the human body.

The application belongs to the technical field of biological medicine, and particularly relates to application of aesculin B in preparation of a medicine for preventing and / or treating gouty nephropathy. The aesculin B can reduce a kidney index, reduce contents of serum creatinine, urea nitrogen and uric acid, reduce kidney crystal precipitates and resist renal interstitial fibrosis, so that an effect of preventing and / or treating gouty nephropathy is achieved.

The invention discloses a starch film slow-release patch for promoting wound healing and a preparation method thereof.The method comprises the steps that 1, silymarin, centella asiatica extract, aescin, aloe polysaccharide, lithospermum erythrorhizon extract, olive oil, lecithin and cetostearyl alcohol polyether are taken and mixed to be uniform, phosphatidylinositol and deionized water are added, low-speed stirring and high-speed shearing are conducted in sequence at the temperature of 25-35 DEG C, and the starch film slow-release patch for promoting wound healing is obtained; the microcrystal nano-emulsion is obtained; 2, adding gelatin and starch into deionized water, heating for 5-15 minutes at 60-80 DEG C while stirring, cooling to 40-50 DEG C, adding citric acid, calcium citrate, glycerol, ethylene glycol and the crystal nano-emulsion, and uniformly mixing to obtain mixed paste liquid; 3, the mixed paste liquid is contained in a vacuumizing container, vacuumizing is conducted, and degassed mixed paste liquid is obtained; 4, carrying out roll forming on the mixed paste to obtain a starch film; and 5, cutting the starch film into the starch film slow-release patch. The starch film sustained-release patch prepared by the invention has good flexibility, viscosity and air permeability, and is capable of stopping bleeding, resisting inflammation and promoting wound healing.

The invention provides a C24-site hydroxylase gene CYP7140E67 of stamen eugenin C, a CYP7140E67 protein and application of the C24-site hydroxylase gene CYP7140E67 and belongs to the technical field of genes. According to the invention, the key enzyme for catalyzing hydroxylation of the C24 site of the stamen eugenin C is successfully found and identified, the blank of research on the catalytic enzyme in aesculus chinensis is filled, and a key gene and a protein coding sequence are provided for biosynthetic pathway analysis and synthetic biology research of the original aescin and derivatives thereof. Moreover, the proaescin is heterogeneously synthesized by expressing the CYP714E67 in the Bensi tobacco leaves, a living body biosynthesis system is constructed, the CYP714E67 is heterogeneously expressed by utilizing saccharomyces cerevisiae, and the in-vitro synthesis of the proaescin is realized by virtue of yeast microsomes, so that a flexible path is provided for industrial production; the problem of resource supply of aescin A is solved, and a solid foundation is laid for promoting cultivation of new varieties of high-yield plants and industrial biosynthesis.

This invention relates to the field of pharmaceuticals, and more particularly to the application of honeysuckle glycosides or verbenacin in alleviating and / or delaying renal fibrosis. This invention has discovered that honeysuckle glycosides can significantly inhibit epithelial-mesenchymal transition, thereby protecting renal function. More unexpectedly, it has been found that the combined use of honeysuckle glycosides and verbenacin significantly enhances the anti-fibrotic effect compared to using either alone, exhibiting a synergistic effect without the serious drawbacks of commonly used clinical drugs. While verbenacin itself possesses certain anti-inflammatory and antioxidant activity, under the experimental conditions of this invention, the anti-fibrotic effect of verbenacin alone is weaker than that of honeysuckle glycosides; however, when used in combination with honeysuckle glycosides, the latter's anti-fibrotic effect is significantly enhanced, suggesting a complementary or synergistic molecular mechanism between the two. Therefore, honeysuckle glycosides, used alone or in combination with verbenacin, has a potent and low-toxicity therapeutic effect on renal fibrosis. Furthermore, both honeysuckle glycosides and verbenacin are natural compounds, low in toxicity, and readily accepted by the human body.